The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt

BJU International

Volumn 96, Issue 3, 2005, Pages 416-422

  Chiang, George J ^a   Billmeyer, Brian R ^a   Canes, David ^a   Stoffel, John ^a   Moinzadeh, Alireza ^a   Austin, Christina A ^b   Kosakowski, Monika ^b   Rieger Christ, Kimberly M ^a,b   Libertino, John A ^a   Summerhayes, Ian C ^a,b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Robert E Wise MD Research and Education Institute   (United States)

Author keywords

Akt signalling; Bladder; Carcinoma; Invasion; PP2

Indexed keywords

CADHERIN; CATENIN; PLAKOGLOBIN; PROTEIN KINASE B BETA; PROTEIN KINASE INHIBITOR PP2; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

BETA CATENIN; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DESMOPLAKINS; GAMMA CATENIN; HUMANS; LETHAL DOSE 50; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; TRANS-ACTIVATORS; URINARY BLADDER NEOPLASMS;

EID: 23244442409     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05642.x     Document Type: Article

References (36)

1. Nam N-H, Parang K. Current targets for anticancer drug discovery. Current Drug Targets 2003; 4: 159-79
2. Sternberg CN, Vgelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003; 46: S105-S115
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
4. Steinberg DM, Kim HL, Sachdeva K, Curti B. Bladder Cancer. Available at http://www.emedicine.com
5. Calabro F, Sternberg CN. Localized and locally advanced bladder cancer. Curr Treatment Options Oncol 2002; 3: 413-28
6. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Eng J Med 1994; 331: 1259-64
7. Williamson MP, Elder PA, Knowles MA. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer 1994; 9: 108-18
8. Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251-6
9. Logothetis CJ, Xu H-J, Ro JY et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst. 1992; 84: 1256-61
10. Grossman HB, Liebert M, Antelo M et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4: 829-34
11. Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 15: 1090-4
12. Cordon-Cardo C1 Zhang Z-F, Dalbagni G et al. Cooperative effects of p53 and Rb alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-21
13. Knowles MA. What could we do now: molecular pathology of bladder cancer. Mol Pathol 2001; 54: 215-21
14. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-19
15. Frixen UH, Behrens J, Sachs M et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85
16. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 3241-5
17. Rieger-Christ KM, Cain JW, Braasch JW et al. Expression of classic cadherins type I in urothelial neoplastic progression. Human Pathol 2001; 32: 18-23
18. Rieger-Christ KM, Lee P, Zagha R et al. Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway. Oncogene 2004; 23: 4745-53
19. cas) in bladder tumors. Cancer Res 1996; 56: 4154-8
20. Syrigos KN, Harrington K, Waxman J, Krausz T, Pignatelli M. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 1998; 160: 1889-93
21. Ribeiro-Filho LA, Franks J, Sasaki M et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 2002; 34: 187-98
22. Horikawa Y, Sugano K, Shigyo M et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high-grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol 2003; 169: 1541-5
23. Canes D, Chiang GJ, Billmeyer BR et al. Histone deacetylase inhibitors up-regulate plakoglobin expression in bladder carcinoma cells and display anti-neoplastic activity in vitro and in vivo. Int J Cancer 2005; 113: 841-8
24. Shim JS, Kim DH, Kwon HJ. Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene 2004; 23: 1704-11
25. Nam J-S, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human colon cancer cells and reduces cancer metastasis. Clin Cancer Res 2002; 8: 2430-6
26. Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exptl Cell Res 2003; 291: 70-82
27. Irby RB, Yeatman TJ. Role of src expression and activation in human cancer. Oncogene 2000; 19: 5636-42
28. Frame MC. Src in cancer, deregulation and consequences of cell behavior. Biochim Biophys Acta 2002; 1602: 114-30
29. c-src in low-grade bladder carcinomas. Cancer Res 1992; 52: 1457-62
30. Rieger KM, Little AF, Swart J et al. Human bladder carcinoma cell lines as indicators of oncogenic events relevant to urothelial neoplastic progression. Br J Cancer; 1995; 72: 683-90
31. Wang DS, Rieger-Christ KM, Latini JM et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinomas. Int J Cancer 2000; 88: 620-5
32. Boyer B, Bourgeois Y, Poupon M-F. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002; 21: 2347-56
33. Winn RA, Bremnes RM, Bemis L et al. Gamma-catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene; 2002; 21: 7497-506
34. Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Ze'ev A. Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 1996; 133: 199-209
35. Tatton L, Morley GM, Chopra R, Khwaja A. The src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 2003; 278: 4847-53
36. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004; 93: 143-50